Advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
Here we draw attention to promising findings for CAR T lupus treatment. The foundations of CAR T, as well as applications for B cell cancers and multiple myeloma, can be found in earlier works in the series.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.”
The first installment lays the foundation for understanding how CAR T works. This second piece delves into the use of CAR T to treat B cell cancers.
This first installment will lay the foundation for understanding how CAR T works. Future installments will focus on CAR T applications and recent innovations which further the field.
This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.
Read More